Abstract
We discuss possible gene therapies for the treatment of ischemic diseases in the central nervous system (CNS). These therapies aim at the prevention of carotid artery restenosis, stimulation of angiogenesis for ischemic brain, protection of neurons against ischemia, and prevention of vasospasm due to subarachnoid hemorrhage (SAH). Carotid artery restenosis can perhaps be approached by preventing vascular smooth muscle cell proliferation via gene therapy in addition to surgical treatment. Cerebral angiogenesis therapy might be applicable to moyamoya disease. Gene therapies with VEGF and HGF to stimulate angiogenesis have been successful in muscle, however, efficacy in the CNS is unknown. Gene transfection efficiency of viral vectors has been poor in the CNS, and the safety of such vectors is questionable. Therefore, development of gene therapy is for neural protection and prevention of vasospasm due to SAH has been limited. Infusion of HVJ-AVE liposomes into monkey cerebrospinal fluid (CSF) space yielded wide-spread gene transfection. HVJ-AVE liposomes may be a promising vector for use in the human CNS. Few currently available gene therapies appear to be options for clinical treatment of cerebral ischemia despite many experimental designs. In addition to the inherent difficulties of treating the CNS, vectors and methods for introducing vectors into the CNS must be improved.
Keywords: ischemic brain disease, gene therapy, hvj-ave, subarachinoid, subarachinoid hemorrhage
Current Gene Therapy
Title: Gene Therapy for Ischemic Brain Diseases
Volume: 3 Issue: 1
Author(s): Youichi Saitoh, Amami Kato, Yasushi Hagihara, Yasufumi Kaneda and Toshiki Yoshimine
Affiliation:
Keywords: ischemic brain disease, gene therapy, hvj-ave, subarachinoid, subarachinoid hemorrhage
Abstract: We discuss possible gene therapies for the treatment of ischemic diseases in the central nervous system (CNS). These therapies aim at the prevention of carotid artery restenosis, stimulation of angiogenesis for ischemic brain, protection of neurons against ischemia, and prevention of vasospasm due to subarachnoid hemorrhage (SAH). Carotid artery restenosis can perhaps be approached by preventing vascular smooth muscle cell proliferation via gene therapy in addition to surgical treatment. Cerebral angiogenesis therapy might be applicable to moyamoya disease. Gene therapies with VEGF and HGF to stimulate angiogenesis have been successful in muscle, however, efficacy in the CNS is unknown. Gene transfection efficiency of viral vectors has been poor in the CNS, and the safety of such vectors is questionable. Therefore, development of gene therapy is for neural protection and prevention of vasospasm due to SAH has been limited. Infusion of HVJ-AVE liposomes into monkey cerebrospinal fluid (CSF) space yielded wide-spread gene transfection. HVJ-AVE liposomes may be a promising vector for use in the human CNS. Few currently available gene therapies appear to be options for clinical treatment of cerebral ischemia despite many experimental designs. In addition to the inherent difficulties of treating the CNS, vectors and methods for introducing vectors into the CNS must be improved.
Export Options
About this article
Cite this article as:
Saitoh Youichi, Kato Amami, Hagihara Yasushi, Kaneda Yasufumi and Yoshimine Toshiki, Gene Therapy for Ischemic Brain Diseases, Current Gene Therapy 2003; 3 (1) . https://dx.doi.org/10.2174/1566523033347561
DOI https://dx.doi.org/10.2174/1566523033347561 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Erythropoietin in Stroke Therapy: Friend or Foe
Current Medicinal Chemistry Multi-element Analyses and Chemical-physical Investigations of Food Samples
Current Nutrition & Food Science Monoclonal Antibodies Against Viruses and Bacteria: A Survey of Patents
Recent Patents on Anti-Infective Drug Discovery New Designer Drugs (Synthetic Cannabinoids and Synthetic Cathinones): Review of Literature
Current Pharmaceutical Design Pharmacokinetics of Antifungal Agents in Neonates and Young Infants
Current Medicinal Chemistry Potential Therapeutic Relevance of CRISPR/Cas9 Guided Epigenetic Regulations for Neuropsychiatric Disorders
Current Topics in Medicinal Chemistry Biomarkers and Novel Therapeutic Targets in Gastrointestinal Stromal Tumors (GISTs)
Recent Patents on Anti-Cancer Drug Discovery Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery The “Aged Garlic Extract” (AGE) and One of its Active Ingredients S-Allyl-LCysteine (SAC) as Potential Preventive and Therapeutic Agents for Alzheimer's Disease (AD)
Current Medicinal Chemistry Pathophysiology of NASH: Perspectives for a Targeted Treatment
Current Pharmaceutical Design A Novel 99mTc-labeled Diphosphonic Acid as Potential Bone Seeking Agent: Synthesis and Biological Evaluation
Current Radiopharmaceuticals Systemic Lupus Erythematosus-Related Interstitial Lung Disease
Current Rheumatology Reviews Agave (Agave spp.) and its Traditional Products as a Source of Bioactive Compounds
Current Bioactive Compounds The Application of Mass Spectrometry to Proteomics and Metabolomics in Biomarker Discovery and Drug Development
Current Molecular Pharmacology Biologic Therapies in Primary Sjögren's Syndrome
Current Pharmaceutical Biotechnology Modulators of Nucleoside Metabolism in the Therapy of Brain Diseases
Current Topics in Medicinal Chemistry Challenges and Opportunities of Nanotechnological based Approach for the Treatment of Tuberculosis
Current Pharmaceutical Design Effect of Chirality on Resonant Behavior of Single Walled BN Nanotube Based Nanomechanical Resonator
Current Nanoscience Editorial [Hot Topic: Current Drug Targets in Childhood Acute Leukemia (Guest Editor: R.B. Lock)]
Current Drug Targets Interstitial Lung Disease in Idiopathic Inflammatory Myopathy
Current Rheumatology Reviews